ng28南宫

History

Eisai China Inc. is a pharmaceutical company wholly-owned by Eisai Co., Ltd. (Eisai), a Japanese multinational pharmaceutical company headquartered in Tokyo, with strong R&D capabilities. Eisai has been smoothly developing its business in China since the early 1990s, Eisai China, Inc. currently promotes more than 10 pharmaceutical brands in China, specializing in the Central Nervous System, Digestive System, Endocrine and Orthopedic areas.

Chapter 1 Shenyang Eisai, Business Initial（1991-1995）
1991 Shenyang Eisai Pharmaceutical Co., Ltd. was established.
1993 Production of NEQ tablet officially started in China.
Chapter 2 Suzhou Eisai, Product Localization（1996-2001）
1996 Eisai(Suzhou)Pharmaceutical Co., Ltd. was established.
1997 Mecobalamin Injection and Neuqinon were launched in China.
1998 Eisai(Suzhou)Pharmaceutical Co., Ltd. obtained GMP certification.
1999 Production of Eisai Suzhou officially started in May, Merislon and Myonal were launched in China.
Chapter 3 Eisai China Inc., Product Line Enrichment（2002-2014）
2002 Company Name was officially changed to Eisai China Inc.
2003-2006 Mecobalamin sugar-coated tablet, Aricept, Fareston, Pariet, Selbex, and Stronger Neo-Minophagen C were launched in China.
2009-2014 Eisai China Inc. established 9 branches in Beijing, Guangzhou, Chengdu, Xi’an, Shenyang, Hangzhou, Qingdao, Tianjin, and Fuzhou.
2010 Eisai (Suzhou) Trading Co., Ltd. was established.

Glakay were launched in China.
2014 Mecobalamin film-coated tablet was launched in China.
Chapter 4 Eisai China Holdings, Enterprise Group Development（2014-now）
2014 Eisai China Holdings Ltd. was established and China Region was set up.
Eisai China Inc. completed construction of new parenteral facility.
2015 Eisai Liaoning Pharmaceutical Co., Ltd. was established; Eisai China entered the generic drug market in China.
2016 E-WAY 2025 , a 10-year mid -tern plan, was official launched.
2017 Eisai China Inc. completed construction of oral solid dose production facility.
2017 Aricept was approved for SAD indication in China; Stalevo and Comtan were introduced to China.
2018 Cidine and Lenvima were launched in China.
2019 Halaven and Fycompa were launched in China.
2020 Unlimit Health Limited (Joint Venture) was established.
Eisai China launched 4 New Strategies: New Products, New Channel, New Platform and New Business.
2021 “EWAY Future & Beyond” was started.
“Yin-Fa-Tong” obtained Internet Hospital License by Health Commission of Jing’an District of Shanghai.
2022 EHK officially managed by Eisai China.

Manufacturing

南宫NG28(中国)官方网站-登录入口

· MANUFACTURING

As part of Eisai’s global manufacturing system, Eisai Suzhou factory carries out all manufacturing processes from local production of tablets, capsules and injections to the repackaging of the imported semi-products. The factory sits on a sprawling land of 25,000m2?in Suzhou Industrial Park and is equipped with state-of-the-art machineries. In 2004, the total investment of Eisai increased to $110 million, while its registered capital increased to $38.54 million. In order to improve its production capacity, Eisai began the construction of the second building of production in 2005 thereby enabling the Suzhou factory to meet increasing demands for high quality Eisai medicines not only in China but elsewhere in the world where it supplies those medicines. To sustain expanding operations in China, in 2010, Eisai increased the total investment to $230 million and the registered capital to $78.54 million, and purchased about 134,000m2?of land in Suzhou Industrial Park for construction of a new facility that will combine R&D, production and logistics. The Eisai Injection Plant in Suzhou Industrial Park was completed on November 18th?2014. Currently, it has obtained the GMP certificate to conduct the repackaging work of imported small volume injections. The Eisai Suzhou Injection Plant, which covers an area of 3,500m2?and a structure area of 6,200m2, will be used as the main production base of mecobalamin injection at the beginning, with an annual production capacity of 60 million vials. In the future, this new facility will become one of Eisai’s Knowledge Centers in the world.

 

· LOCALLY MANUFACTURED PRODUCTS

Mecobalamin tablets, betahistine mesylate tablets, donepezil hydrochloride tablets, eperisone hydrochloride tablets, coenzyme Q10 tablets, teprenone capsules, and sodium rabeprazole enteric coating tablets

 

· REPACKAGED IMPORTED PRODUCTS

Mecobalamin injection, compound glycyrrhizin, compound glycyrrhizin injection, mitiglinide calcium tablets, and menatetrenone soft capsules

0 Comments/by

Quality Assurance

In line with Eisai’s General Policy on Product Quality (i.e.?“The quality of every single tablet, capsule and ampoule that we produce is integral to the life of the patient”), Eisai China, Inc. is committed to ensuring that only high quality products come out of its Suzhou factory. To this end, all manufacturing operations in the plant are carried out in accordance with GMP. Our Quality Assurance people make sure that all necessary and required procedures are undertaken to ensure the identity and purity of Eisai products. As part of the overall Quality Assurance system, the Suzhou factory undergoes regular inspection and audit conducted by our parent company and/or regulatory authorities. We continually endeavor to manufacture and supply good quality pharmaceutical products that patients and customers can trust.

 

0 Comments/by

COMMITMENT TO ENVIRONMENTAL PROTECTION

· Environmental Protection

In line with Eisai’s?Environmental Protection Policy, Eisai China Inc. is making every effort to protect the environment and continuously implements cleaner, energy saving production processes at its Suzhou plant. To decrease energy consumption, we have installed high-efficient illumination system, energy-saving lamps and other energy-saving equipment in the plant. Taking advantage of advanced plate heat exchanger, we are able to recycle heat from steam condensate, thereby reducing the steam consumption. Also, we install the outdoor cooling tower to increase the use of recycled water while reducing the fresh water consumption. Additionally, our Membrane Bio-Reactor (MBR) sewage treatment system follows internal standards for environmental emissions that are stricter than the national standards. As a result of these efforts, Eisai Suzhou’s total expenditures on water, electricity and gas have been declining year by year. Our plant consistently sticks to waste classification and strictly implements requirements of hazardous waste disposal control, with a steady waste recovery rate of more than 80%. Each year, we will set CO2 emission target and work hard to achieve such target. We have made every effort to provide protection and safety to all workers at the plant, and have increased their environment protection awareness through education and training. The effective ISO14001 environment management system and OHSAS18001 occupational health and safety management system that we established in Suzhou plant have been approved by British Standards Institution (BSI). As an?hhc?company, we strive for continual improvement in our system to minimize any detrimental effects of our operations and products on the environment.

 

· Eisai’s Environmental Protection Policy

“Eisai and its group of companies place global environmental protection as an important component of business operations and strive to maintain the environment.”

0 Comments/by

Company Profile

 

?Eisai China Headquarter

Address: Floor 39-40, Park Place, No. 1601, Nanjing West Road, Jing’an District, Shanghai
Tel: 86-21-2419-2888 Fax: 86-21-2419-2891
Postal code: 200040
Website：www.eisai.com.cn

 

?Eisai China Holdings Ltd.

Eisai China Inc.
Registered Address: No.168, Xingpu Road, Suzhou Industrial Park, Suzhou
Tel: 86-512-69566776 Fax: 86-512-67618640? Postal code: 215021

 

?Eisai (Liaoning) Pharmaceutical Co., Ltd.

Registered Address: No.39, Pingtai 2nd Street, High-tech Industrial Development Zone, Benxi, Liaoning Province
Tel: 86-24-45598788 Fax: 86-24-45598789 Postal code: 117004

 

?Eisai (Suzhou) Trading Co., Ltd.

Registered Address: No.168, Xingpu Road, Suzhou Industrial Park, Suzhou
Tel: 86-512-67903966 Fax: 86-512-67903941 Postal code: 215126

 

?Suzhou Factory (ISO14001 Certified)

No.168, Xingpu Road, Suzhou Industrial Park, Suzhou
Tel: 86-512- 69566776 Fax: 86-512-67618640 Postal code: 215021

0 Comments/by

PRESIDENT’S MESSAGE

南宫NG28(中国)官方网站-登录入口
It has been 32 years since Eisai came to China in 1991. It is fair to say that Eisai’s relationship with China is long-standing and well-established. Prof. Hans Mueller, Vice President of Beijing Medical College (now Peking University Health Science Center) and his wife together with their team visited Kawashima Plant in 1972 when China and Japan had not established diplomatic relations. Under the Chinese National Flag at Kawashima Plant, Mr. Hiroshi Kimura and the leaders of the Plant welcomed and received the Vice President Muller and his team. This was the first time of the Chinese National Flag raising on Japanese land and laid a firm and lasting foundation for the relationship between Eisai and China. Eisai China has also witnessed the rapid development of China’s economy as well as the prosperity and peace in China.

 

The world pharmaceutical market has been in the era of globalization. The pharmaceutical market in developed countries tends to be mature, while the market in emerging developing countries is in the stage of rapid growth. Beyond the continuous reform and opening-up as well as the growth of national power, China, as the largest developing country, has been stepping up the reform of the healthcare system and dramatically increasing capital investment and market opening-up in recent years. The people’s concern and purchasing power in the healthcare field have also been increasing. I believe that the prospect of the Chinese pharmaceutical industry will be broader and more splendid. Eisai China will also have a broader and diversified development space and will continue to grow and expand with China.

The rapid development of China’s pharmaceutical industry has attracted a worldwide attention. Seen from the global business structure of Eisai, China has become a very important market now and in the future, and we are closely surrounding the strategic deployment of EWAY 2025, adhering to the human health care (hhc) philosophy, and taking “hhc, Innovation, Access, and Autonomy” as the core cornerstones. We believe that Eisai China will become a respectable pharmaceutical enterprise with?hhc.

For the future development in the Chinese market, we hope that we could bring more benefits to Chinese patients and their families. Eisai China will launch successively new products in the fields of neurology and oncology. Meanwhile, Eisai China will actively expand the market coverage including the low-tier market. In addition to large cities and major hospitals, we are going to cover small cities and healthcare facilities with Eisai’s products and bring Eisai’s products to more patients in China. The interests of patients and their families are our priority and we will contribute to improving their well-beings.

Eisai China has been persistently practicing Eisai’s?hhc?philosophy and continuously encouraging all employees to contribute to the society, especially to the patients and their families. We will find out the significance of the Eisai’s philosophy when we fully understand the connotation and extension of?hhc. Our personal values can be reflected only by understanding the needs and interests of patients, giving them the top priority and constantly improving their healthcare satisfaction. Eisai China encourages its employees to spend 1% of their business time with patients. Eisai China carries out hundreds of?hhc?activities each year. The?hhc?philosophy is the original aspiration of Eisai. The very beginning mind itself is the most accomplished mind of true enlightenment. I hope that every Eisai staff can always keep the original aspiration in their minds when considering issues and making decisions in their work and use practical actions to achieve the goal of?hhc.

Eisai Co.,Ltd. Senior Vice President
Eisai China Holdings Ltd. President
Eisai China Inc. President
Feng Yanhui

0 Comments/by

About Eisai China

Eisai’s affiliates in China are wholly-owned by Eisai Co., Ltd., a Japanese multinational pharmaceutical company headquartered in Tokyo, with strong R&D capabilities. It was founded in1941. Since its foundation, the company has actively expanded into overseas markets and now has sales subsidiaries and factories in America, Europe and Asia.

Eisai China has been smoothly developing its business in China since the early 1990s, now consisting of Eisai China Holdings Ltd., Eisai China Inc., Eisai (Liaoning) Pharmaceutical Co., Ltd. and Eisai (Suzhou) Trading Co., Ltd.

Jobs

At Eisai China Inc., we value our employees and provide them with tools, training, and opportunities to prosper in their careers. We provide competitive compensation and welfare benefits, and continually recognize and reward excellent performance and hard work. We strive to provide a working environment where our employees can maintain a healthy work-life balance. We instill in our employees a strong commitment to our?hhc?philosophy and continually encourage them to contribute to the betterment of the healthcare community, particularly the patients and their families. If you believe in commitment and want to contribute to improving the lives of patients while enjoying work-life balance, then Eisai China Inc. is the workplace for you.

 

Please scan QR Code for more positions

Position Location Number Educational Requirement
Intern Medical Representative China Several Bachelor degree or above
Medical Representative China Several College degree or above
District Sales Manager China Several College degree or above
Regional Promotion Manager China Several College degree or above
Product Manager Shanghai Several Bachelor degree or above
0 Comments/by

CSR

In pursuit of its?human health care philosophy, Eisai China Inc. strives to maintain the highest GMP standard in manufacturing products and strictly adheres to the highest level of ethics and compliance. Through this commitment, Eisai China Inc not only provides high-quality, eco-friendly, safe and satisfactory products and services to patients and their families, but also proactively contribute to society by supporting programs and activities that help promote the advancement of medical sciences (e.g. “Eisai Scholarship Award”), increase awareness about diseases (e.g. “Yellow Handkerchief Love Action”), and provide aide in times of disasters.

May

Eisai China donated 700,000 yuan worth of digestive system medicine to Anxiang County, Hunan Province.

南宫NG28(中国)官方网站-登录入口

April

Eisai China donated 50,000 yuan to the “Just Charity – Jing ‘an Liren Hui Special Fund” to fund public welfare activities related to women and children.

南宫NG28(中国)官方网站-登录入口

March

Eisai China won the 2023 Charity Enterprise Award at the 8th China Charity Annual Meeting

南宫NG28(中国)官方网站-登录入口

Eisai China awarded “Jiangsu Green Factory”

南宫NG28(中国)官方网站-登录入口

Eisai China Scholarship Award Ceremony was successfully held at School of Basic Medical, Fudan University

南宫NG28(中国)官方网站-登录入口

Eisai China Scholarship Award Ceremony was successfully held at School of Business Administration, Shenyang Pharmaceutical University

南宫NG28(中国)官方网站-登录入口

February

Eisai to boost initiatives on greenhouse gas reduction, aiming to achieve net zero by 2050.

January

Top Employer China 2024

南宫NG28(中国)官方网站-登录入口

Eisai China Scholarship Award Ceremony was successfully held at School of Pharmacy, Xi’an Jiaotong University.

南宫NG28(中国)官方网站-登录入口

2023

December

Eisai China Scholarship Award Ceremony was successfully held at School of Pharmacy, China Pharmaceutical University.

南宫NG28(中国)官方网站-登录入口

Eisai China Scholarship Award Ceremony was successfully held at Peking University Health Science Center

南宫NG28(中国)官方网站-登录入口

November

At the Expo, Eisai China together with Sinotau, KingMed, HTA Co., Medi Trust and Yin Fa Tong jointly proposed and built China’s brain health industry ecosystem.

October

The OSD of Suzhou Plant won the Suzhou City-level Model Intelligent Workshop.

September

On World Alzheimer’s Day, Eisai has released a dementia awareness video, “Life Goes On 2023: Two Memories, One Story” globally.
南宫NG28(中国)官方网站-登录入口


Alzheimer’s Disease Handbook 2023 released.
南宫NG28(中国)官方网站-登录入口

 

“Le-Guan-Xiang-Qian”–Patient Assistance Program for Liver Cancer in County Areas is launched.

南宫NG28(中国)官方网站-登录入口

 

July

Eisai China and Shanghai Yinfatong Internet Hospital (a subsidiary of Unlimit Health Limited) launched the “Memory and Love” – A Brain Health Care Program for the Elderly.

南宫NG28(中国)官方网站-登录入口

 

Eisai China Calls for “Concern for Brain Health, Early Detection, Early Diagnosis, Early Intervention” at the “2023China Brain Health Conference.”

南宫NG28(中国)官方网站-登录入口

 

June

Suzhou plant successfully completed the 2022 greenhouse gas and product carbon foot-printing.
南宫NG28(中国)官方网站-登录入口

Suzhou plant successfully passed the energy management system certification.

南宫NG28(中国)官方网站-登录入口

Eisai China Scholarship Award Ceremony was successfully held at School of Business Administration, Shenyang Pharmaceutical University.

南宫NG28(中国)官方网站-登录入口

 

March

The “Hai-Yun-Xin-Sheng” breast cancer PAP

In order to help more patients diagnosed with breast cancer to receive timely and effective treatment, reduce their financial burden and prolong their lives, the China Primary Health Care Foundation launched the “Hai-Yun-Xin-Sheng” Breast Cancer Patient Assistance Project (PAP) in September 2020, and Eisai provided free drug Halaven to the China Primary Health Care Foundation. As of March 2023, there are 207 low-insurance patients and 2,204 low-income patients with 25,687 injection for a cumulative donation value of RMB 102.2 million.

 

“Wei-Ai-Xin-Sheng” PAP

In order to help more patients diagnosed with hepatocellular carcinoma to receive timely and effective treatment, reduce their financial burden and prolong their lives, China Charity Federation launched the “Wei-Ai-Xin-Sheng” Patient Assistance Project (PAP) in December 2022, and Eisai provided free Levima to China Charity Federation, which aims to help patients with hepatocellular carcinoma to receive more durable and effective medical treatment and improve their quality of life.

 

January

Top Employer China 2023

南宫NG28(中国)官方网站-登录入口

0 Comments/by

Compliance

The Compliance Counter serves as a point of contact for the whistle-blowing system and consultation resource in Eisai China which aims to creat an environment that serves to further promote compliance.

It is also a consultation/contact resource that all officers, employees and business partner can use to seek assistance with interpreting provisions and finding answers to questions about whether their own conduct, or the conduct of their supervisors or co-workers conforms to the compliance policies.

The Compliance Counter handles many topics, including harassment, ethics guidelines for public servants and industry self-regulation.

The Compliance Counter also provides resources such as whistle-blowing system operated by outside lawyers.

The information of Compliance Counter is shown in below：

1、Internal Counter：
【We accept real-name report and anonymous report.False accusation is prohibited】
Email：compliance@eisai.com.cn
Direct line：199-0179-8449
WeChat：eisaicompliance

2、External Counter ：
【We accept real-name report and anonymous report.False accusation is prohibited】
Mr Yamane from TMI law office（Fluent in Chinese English and Japanese）
Email：compliance@tmish.com
Office line：021-5465-2233
Direct line：189-1829-0209

3、hhc Global Helpline：
https://hhcGlobalHelpline.whistle.jp

南宫NG28(中国)官方网站-登录入口

0 Comments/by

Copyright(c) 2011 Eisai China lnc.All Rights Reserved.
沪ICP备11005394号-1
沪公网安备31010602001439号

Customer Service Hotline

021-62881220

LINKS

? Record information of Representative
? 已上市替普瑞酮胶囊铬限量检验报告公示说明

More Information

? Privacy Policy
? Legal Notices
? Accessibility

网站地图